Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), stock finished the Tuesday’s session 6.84% higher at $2.03. A total of 1.47 million shares were traded, which was below its three months average volume of 1.98 million shares. The stock vacillated between $1.88 and $2.05 during the session. Over the previous three trading sessions and over the last one month, Prana Biotechnology Ltd’s shares have surged 14.69% and 20.83%, respectively. However, from the beginning of 2014, the company’s stock has declined 71.04%. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), weekly performance is 12.15%. On last trading day company shares ended up $2.03. Analysts mean target price for the company is $4.00. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), distance from 50-day simple moving average (SMA50) is 0.33%.
Clovis Oncology Inc (NASDAQ:CLVS), was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, TheFlyOnTheWall.com reports. The firm currently has a $50.00 price target on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 25.25% from the company’s current price. Clovis Oncology Inc (NASDAQ:CLVS), advanced 7.39% in last trading session and ended the day on $44.74. CLVS, return on assets is -19.80%. Clovis Oncology Inc (NASDAQ:CLVS), quarterly performance is -45.35%.
Analysts at Empire Asset Management initiated coverage on shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating and a $6.00 price target on the stock. Empire Asset Management’s price target suggests a potential downside of 56.40% from the company’s current price. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), shares moved up 8.72% in last trading session and was closed at $14.96, while trading in range of $13.88 – 15.08. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), year to date (YTD) performance is 20.55%.
Global Markets Direct’s, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Product Pipeline Review – 2014′, provides an overview of the Lexicon Pharmaceuticals, Inc.’s pharmaceutical research and development focus. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), ended the last trading day at $1.76. Company weekly volatility is calculated as 9.59% and price to cash ratio as 9.26. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), showed a negative weekly performance of 35.38%.
Galena Biopharma Inc (NASDAQ:GALE)’s shares jumped 4.85% to $2.81. The company on June 2 announced that data from the Company’s Phase 1 study with GALE-301, or Folate Binding Protein (FBP), was presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting. The poster entitled, “Comparison of recurrent and nonrecurrent ovarian and uterine cancer patients undergoing adjuvant folate receptor vaccine therapy,” was presented during the Gynecologic Cancer General Poster Session. Galena Biopharma Inc (NASDAQ:GALE), weekly performance is 42.92%. On last trading day company shares ended up $3.13. Analysts mean target price for the company is $6.88. Galena Biopharma Inc (NASDAQ:GALE), distance from 50-day simple moving average (SMA50) is 37.12%.